Great find!
(like any cancer, they would need to do preclinical study and then human trials to confirm that Bisantrene is effective for treating Liver Cancer via an FTO pathway)
This just confirms that FTO is relevant for Liver Cancer.
Each one of these identified, increases the possibility that Bisantrene will eventually as an FTO-targeting agent achieve revenues at similar levels to Keytruda.
Current forecast for 2026 Keytruda sales around USD $25B.
Here's a list of all the indications Keytruda is now approved for. Currently 30.
Pillar 1 - FTO (new thread), page-23
-
- There are more pages in this discussion • 2,920 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.84 |
Change
-0.025(1.34%) |
Mkt cap ! $313.3M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.91 | $1.81 | $257.6K | 138.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 26825 | $1.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.90 | 759 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |